A phase II trial of subcutaneous Amifostine and radiation therapy in patients with head and neck cancer

被引：39
作者：
Anné, PR
Curran, WJ
机构：
[1] Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA USA
[2] Med Oncol Allegheny Gen Hosp, Pittsburgh, PA USA
来源：
SEMINARS IN RADIATION ONCOLOGY | 2002年 / 12卷 / 01期
关键词：
D O I：
10.1053/srao.2002.31358
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
[21]   Randomized phase III trial of postoperative radiochemotherapy ± amifostine in head and neck cancer -: Is there evidence for radioprotection? [J].
Vacha, P ;
Fehlauer, F ;
Mahlmann, B ;
Marx, M ;
Hinke, A ;
Sommer, K ;
Richter, E ;
Feyerabend, T .
STRAHLENTHERAPIE UND ONKOLOGIE, 2003, 179 (06) :385-389
[22]   Randomized phase II study of concomitant chemoradiation using weekly carboplatin/paclitaxel/concomitant boost radiation with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced head and neck cancer [J].
Haddad, R. ;
Braschayko, P. ;
Sonis, S. ;
Posner, M. ;
Wirth, L. ;
Tishler, R. .
ORAL ONCOLOGY, 2009, :65-65
[23]   Subcutaneous Compared With Intravenous Administration of Amifostine in Patients With Head and Neck Cancer Receiving Radiotherapy: Final Results of the GORTEC 2000-02 Phase III Randomized Trial [J].
Bardet, Etienne ;
Martin, Laurent ;
Calais, Gilles ;
Alfonsi, Marc ;
Feham, Nasr Eddine ;
Tuchais, Claude ;
Boisselier, Pierre ;
Dessard-Diana, Bernadette ;
Seng, Sok-Hun ;
Garaud, Pascal ;
Auperin, Anne ;
Bourhis, Jean .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) :127-133
[24]   Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer [J].
Argiris, Athanassios ;
Karamouzis, Michalis V. ;
Gooding, William E. ;
Branstetter, Barton F. ;
Zhong, Shilong ;
Raez, Luis E. ;
Savvides, Panayiotis ;
Romkes, Marjorie .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) :1140-1145
[25]   PHASE-II TRIAL OF MITOGUAZONE IN PATIENTS WITH RECURRENT HEAD AND NECK-CANCER [J].
CONINX, P ;
NASCA, S ;
JEZEKOVA, D ;
ROELANDT, H ;
MOREL, M ;
LEGROS, M ;
CATTAN, A .
BULLETIN DU CANCER, 1985, 72 (02) :153-154
[26]   PHASE-II TRIAL OF MITOGUAZONE IN PATIENTS WITH ADVANCED HEAD AND NECK-CANCER [J].
THONGPRASERT, S ;
BOSL, GJ ;
GELLER, NL ;
WITTES, RE .
CANCER TREATMENT REPORTS, 1984, 68 (10) :1301-1302
[27]   Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer [J].
Lee, Maverick G. L. ;
Freeman, Amanda R. ;
Roos, Daniel E. ;
Milner, Alvin D. ;
Borg, Martin F. .
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2019, 63 (01) :142-150
[28]   Amifostine in the Treatment of Head and Neck Cancer: Intravenous Administration, Subcutaneous Administration, or None of the Above [J].
Eisbruch, Avraham .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) :119-121
[29]   Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck canceraEuro [J].
Argiris, A. ;
Bauman, J. E. ;
Ohr, J. ;
Gooding, W. E. ;
Heron, D. E. ;
Duvvuri, U. ;
Kubicek, G. J. ;
Posluszny, D. M. ;
Vassilakopoulou, M. ;
Kim, S. ;
Grandis, J. R. ;
Johnson, J. T. ;
Gibson, M. K. ;
Clump, D. A. ;
Flaherty, J. T. ;
Chiosea, S. I. ;
Branstetter, B. ;
Ferris, R. L. .
ANNALS OF ONCOLOGY, 2016, 27 (08) :1594-1600
[30]   Report from ASCO 2004 - Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients [J].
不详 .
ONCOLOGY-NEW YORK, 2004, 18 (10) :1314-+
12345